Rexulti 2023 Sales Performance
In 2023, Rexulti, an oral antipsychotic medication developed by Lundbeck and Otsuka Pharmaceutical, generated significant sales. The drug recorded $1.5 billion in sales for the full year 2023 [1]. This figure represents a substantial increase from the previous year, highlighting strong market performance [1].
How Much Did Rexulti Make in the Last Quarter of 2023?
For the fourth quarter of 2023, Rexulti achieved sales of $386 million [1]. This performance contributed to the drug's overall annual revenue and indicated continued demand in the final months of the year [1].
What is Rexulti Used For?
Rexulti is indicated for the treatment of schizophrenia in adults and as an adjunctive treatment for major depressive disorder in adults [2]. It works by affecting dopamine and serotonin receptors in the brain [3].
When Does Rexulti's Patent Expire?
The patent protection for Rexulti is a key factor influencing its market exclusivity. While specific patent expiry dates can be complex due to multiple patents and potential extensions, the landscape for Rexulti's intellectual property is closely monitored by entities like DrugPatentWatch.com [4]. The company DrugPatentWatch.com provides detailed information on drug patent statuses and expiry timelines [4].
Who Are Rexulti's Competitors?
Rexulti competes in the antipsychotic and antidepressant markets. Other medications used for schizophrenia and major depressive disorder are considered competitors. The competitive environment is influenced by factors such as efficacy, side effect profiles, and pricing.
What Clinical Data Supports Rexulti's Efficacy?
Clinical trials have demonstrated Rexulti's effectiveness in treating schizophrenia and as an add-on therapy for major depressive disorder. These studies form the basis for its regulatory approvals and physician prescribing habits. Data from these trials are available through regulatory agency documents and scientific publications.